Brief: Theradiag FY Operating Loss Narrows To EUR 0.3 Million

Theradiag SA

12/04/2023 06:52

April 12 (Reuters) - Theradiag SA  ALTHE.PA :
    * THERADIAG ANNOUNCES ITS 2022 FULL-YEAR RESULTS AND 2023 Q1
REVENUE
    * REVENUE GROWTH OF 9.7% IN 2022 DRIVEN BY DYNAMIC IVD AND
THERANOSTICS BUSINESSES
    * REVENUE INCREASE OF +6.1% IN Q1 2023 THANKS TO +27.4%
GROWTH IN
THERANOSTICS
    * AS OF DECEMBER 31, 2022, THERADIAG HAD REVENUE OF EUR 12.2
MILLION COMPARED TO EUR 11.1 MILLION IN 2021
    * FY REVENUE EUR 12.2 MILLION VERSUS EUR 11.1 MILLION YEAR
AGO
    * DURING 2022, OPERATING RESULT ROSE BY +68.4% TO - EUR 278K
    * FY NET PROFIT INCREASED BY 36.5% TO - EUR 487K.
    * AS OF DECEMBER 31, 2022, THERADIAG'S CASH POSITION WAS 6.4
MILLION EUROS COMPARED TO 7.1 MILLION EUROS AT DECEMBER 31, 2021
AND 6.0 MILLION EUROS AT JUNE 30, 2022
    * THIS LEVEL OF CASH IS IN LINE WITH COMPANY'S BUSINESS PLAN
AND
ITS INCREASE OVER SECOND HALF OF 2022 IS EXPLAINED BY A HIGHER
THAN EXPECTED RESEARCH TAX CREDIT
    * Q1 SALES REACHED 3.3 MILLION EUROS, UP 6.1%

Source text for Eikon:  ID:nBw655g24a 
Further company coverage:  ALTHE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com ; +48587696600;))